|
|
Vaccine Detail
|
MVF-HER-2(628-647)-CRL 1005 vaccine |
| Vaccine Information |
- Vaccine Name: MVF-HER-2(628-647)-CRL 1005 vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HER-2 (NCT00017537; NCIT_C2637)
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is a chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). The vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. (NCIT_C2637) MVF-HER-2(628-647)-CRL 1005 vaccine may induce anti-HER-2 antibody in patients with metastatic or recurrent cancer (Breast, Ovarian, Non-small cell lung cancer, Gastric adenocarcinoma). (NCT00017537)
|
| Host Response |
|
|
| References |
NCIT_C2637: MVF-HER-2(628-647)-CRL 1005 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637]
NCT00017537: Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer [https://clinicaltrials.gov/study/NCT00017537]
|
|
